LogFAQs > #948075525

monkmith posted...

here @BendoHendo , this pretty well summarizes the current understanding of coronavirus vaccines.

https://link.springer.com/article/10.1007/s40121-020-00300-x#Sec2

search for ADE for your specific question.

Interesting:

The induction of ADE using the S glycoprotein has been tackled by using truncated versions of the same protein. It is believed that the use of the receptor-binding domain (RBD) or the S1 subunit of the S glycoprotein can lead to the induction of neutralizing antibodies while avoiding ADE. The idea is to focus the induction of antibodies to relevant S regions for efficient virus neutralization and, by doing so, to avoid the induction of potential non-neutralizing antibodies targeting other regions of the S protein. Even though there seems to be little direct evidence proving this idea, vaccines based on these regions have already been tested, allowing the induction of high titers of neutralizing antibodies and a certain level of protection in small animals and non-human primates [49, 50, 56, 78].

I guess we will see if using the truncated version of the same protein helps. The paragraph states this has not been proven yet. Hopefully we will know within a couple of years of the vaccine being out. Do we know which vaccines (Moderna, Pfizer, Astrazenica) use the truncated version of the protein?

--